KD mutations identified at relapse according to CR status at transplant and maintenance TKI at relapse
| Maintenance TKI at relapse . | KD mutation . | Total . | |||||
|---|---|---|---|---|---|---|---|
| T315I . | Y253H . | F317I . | T315I, Y253H . | None . | Testing unavailable . | ||
| CR1 | |||||||
| Imatinib | 1 | 3* | 4 | ||||
| Dasatinib | 2 | 2 | 4 | ||||
| Nilotinib | 1 | 2 | 3 | ||||
| Bosutinib | 0 | ||||||
| Ponatinib | 0 | ||||||
| None | 1 | 1 | 2 | 1 | 5 | ||
| CR2+ | |||||||
| Imatinib | 0 | ||||||
| Dasatinib | 1 | 1 | 1* | 3 | |||
| Nilotinib | 1 | 1 | |||||
| Bosutinib | 1 | 1 | |||||
| Ponatinib | 2 | 2 | |||||
| None | 0 | ||||||
| Total | 5 | 4 | 1 | 1 | 3 | 9 | |
| Maintenance TKI at relapse . | KD mutation . | Total . | |||||
|---|---|---|---|---|---|---|---|
| T315I . | Y253H . | F317I . | T315I, Y253H . | None . | Testing unavailable . | ||
| CR1 | |||||||
| Imatinib | 1 | 3* | 4 | ||||
| Dasatinib | 2 | 2 | 4 | ||||
| Nilotinib | 1 | 2 | 3 | ||||
| Bosutinib | 0 | ||||||
| Ponatinib | 0 | ||||||
| None | 1 | 1 | 2 | 1 | 5 | ||
| CR2+ | |||||||
| Imatinib | 0 | ||||||
| Dasatinib | 1 | 1 | 1* | 3 | |||
| Nilotinib | 1 | 1 | |||||
| Bosutinib | 1 | 1 | |||||
| Ponatinib | 2 | 2 | |||||
| None | 0 | ||||||
| Total | 5 | 4 | 1 | 1 | 3 | 9 | |
One patient on imatinib in CR1 and 1 patient on dasatinib in CR2 had isolated central nervous system relapses.